Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Biofrontera (BFRI) over the last 2 years, with Sep 2025 value amounting to $3.0 million.

  • Biofrontera's Accumulated Expenses was N/A to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Biofrontera reported Accumulated Expenses of $3.0 million as of Q3 2025, which was up 23.30% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Accumulated Expenses ranged from a high of $5.6 million in Q1 2022 and a low of $2.4 million during Q2 2025.
  • For the 3-year period, Biofrontera's Accumulated Expenses averaged around $2.6 million, with its median value being $2.5 million (2025).
  • Data for Biofrontera's Accumulated Expenses shows a maximum YoY plummeted of 55.36% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Biofrontera's Accumulated Expenses stood at $2.5 million in 2022, then plummeted by 55.36% to $2.5 million in 2023, then reached $2.4 million in 2024, then reached $3.0 million in 2025.
  • Its Accumulated Expenses stands at $3.0 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.5 million for Q1 2025.